Interplay Between TGF-β Signaling and MicroRNA in Diabetic Cardiomyopathy.

IF 3.1 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiovascular Drugs and Therapy Pub Date : 2025-06-01 Epub Date: 2023-12-20 DOI:10.1007/s10557-023-07532-2

Jianning Qin, Yao Tan, Yang Han, Letian Yu, Shali Liu, Simin Zhao, Hengquan Wan, Shunlin Qu

引用次数: 0

Abstract

In diabetic patients, concomitant cardiovascular disease is the main factor contributing to their morbidity and mortality. Diabetic cardiomyopathy (DCM) is a form of cardiovascular disease associated with diabetes that can result in heart failure. Transforming growth factor-β (TGF-β) isoforms play a crucial role in heart remodeling and repair and are elevated and activated in myocardial disorders. Alterations in certain microRNAs (miRNA) are closely related to diabetic cardiomyopathy. One or more miRNA molecules target the majority of TGF-β pathway components, and TGF-β directly or via SMADs controls miRNA synthesis. Based on these interactions, this review discusses potential cross-talk between TGF-β signaling and miRNA in DCM in order to investigate the creation of potential therapeutic targets.

Abstract Image

查看原文本刊更多论文

糖尿病心肌病中 TGF-β 信号与 MicroRNA 之间的相互作用

在糖尿病患者中，并发心血管疾病是导致其发病率和死亡率的主要因素。糖尿病心肌病（DCM）是一种与糖尿病相关的心血管疾病，可导致心力衰竭。转化生长因子-β（TGF-β）同工酶在心脏重塑和修复中起着至关重要的作用，并在心肌疾病中升高和激活。某些微小核糖核酸（miRNA）的改变与糖尿病心肌病密切相关。一种或多种 miRNA 分子靶向大多数 TGF-β 通路成分，TGF-β 直接或通过 SMADs 控制 miRNA 的合成。基于这些相互作用，本综述讨论了 TGF-β 信号传导与 miRNA 在 DCM 中的潜在交叉作用，以研究潜在治疗靶点的形成。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular Drugs and Therapy 医学-心血管系统

CiteScore

8.30

自引率

0.00%

发文量

110

审稿时长

4.5 months

期刊介绍： Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field. Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients. Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.